Brefeldin A

For research use only.

Catalog No.S7046

20 publications

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Brefeldin A has been cited by 20 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NHf5WlZHfW6ldHnvckBCe3OjeR?= MX[yJO69VQ>? M1fGRVEhcA>? NXnsT2dpcW6qaXLpeJMhfGinIFytSG9RSSBqMkFCpO69VSlvaX7keYNm\CC2cnHud4lmdnRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvcuKh MmfpNlY{PjNzOUG=
C2C12 M2fVfmZ2dmO2aX;uJGF{e2G7 M1P3UFHDqM7:Zz;tcC=> M{XXblHDqGh? NY\iUllZ[WKxbHnzbIV{KGO7dH;rbY5mKHKnbHXhd4Uh\nKxbTDDNmMyOiCveX;0eYJmew>? M1PXWlI3OjlzMke5
MEFs WT MYDGeY5kfGmxbjDBd5NigQ>? MoLMOeKh|ryP NH\KfI0zOCCvaX6= MYPjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT Mnm3NlYyQTZyMkO=
MEFs VAMP7 KO M2\4WmZ2dmO2aX;uJGF{e2G7 M1THdlXDqM7:TR?= NHH6NmMzOCCvaX6= M1rocINifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? MXiyOlE6PjB{Mx?=
SMCs Mm\oSpVv[3Srb36gRZN{[Xl? MonVNVDDqML3Zz;tcC=> M3v5WlAuOTJiaB?= NVrwNWxDTE2VTx?= MU\zbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NUftc21nOjZzN{KwPFA>
SMCs MlXCSpVv[3Srb36gRZN{[Xl? NVv1e5FwOTEEoNM1[{9udA>? NHLOSWExNTF{IHi= NFPtTmFFVVOR M4HrWoNifXOnczDhJJRz[W6|aXXueEBE[TJtwrDy[Yxm[XOnIH\yc40hfGinIFXSM3NTyqB? NIrFSpQzPjF5MkC4NC=>
HEMC-1 NWLZSJpqTnWwY4Tpc44hSXO|YYm= NX3zeGltOC5zwrFCuYcwdWx? NUDye4h4OjUEoHi= MUXjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= NWq3V2l3OjV7N{K3OVk>
HUVEC M1;vdWZ2dmO2aX;uJGF{e2G7 M2i5bFExyqEQvF2= M1\DXFHDqGh? Mn71SG1UVw>? MVThZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? M3;JXFI2QTV4OUi4
HUVEC MXXGeY5kfGmxbjDBd5NigQ>? NFTiPHYyOMLizszN NEm4fFUyyqCq MoPRSG1UVw>? M3nO[olv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= M4HZelI2QTV4OUi4
Caco-2 NUTrZ|RrTnWwY4Tpc44hSXO|YYm= MYCyMlUh|ryP NIPPbHE{OCCvaX6= M4mxfoF1fGWwdXH0[ZMhfGinIGTHSk3PujFvbXXkbYF1\WRiaX7jdoVie2ViaX6gV2VTXCCodX7jeIlwdg>? MkDQNlU6PTR7M{G=
NRK NFqyUHJHfW6ldHnvckBCe3OjeR?= M1LsWVIxOOLChX7nM41t MljaOQKBjWh? MWPEUXNQ MmXNdoV{[3WnczDtbZRwfGmlIIDyc4dz\XO|aX;u M3PFW|I2QTR6NUi2
HeLa NGDxPXZHfW6ldHnvckBCe3OjeR?= NID0S2MzODEkgJXu[{9udA>? NFzwfnY{KGh? NHjKUo1FVVOR MnXzbY5lfWOnczD0bIUh[XK2aX\pZ4lidCCkcnXhb{12eCCxZjD0bIUhT2:uZ3mgZ49ueGyneB?= NXHKRWVGOjV7NEi1PFY>
COS NW\TXm5KTnWwY4Tpc44hSXO|YYm= MVuxJO69\y:vbB?= Mlz5N{Bp MWTjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> NY\STpM2OjV7MUW5NFA>
DF1  NV[5NYZ4TnWwY4Tpc44hSXO|YYm= NUDKSYRIOcLizszNxsA> NV7JRlU6PDhiaB?= NVnUTIRSTE2VTx?= M3PrboRqe3CncoPld:KhfGinIHX4c4dmdm:3czDDV2didE6DY2SyJJBzd3SnaX6= MmDNNlU5ODdyNUS=
nHDFs  NWr6NYExTnWwY4Tpc44hSXO|YYm= NXzFZXgyOcLizszNxsA> NH20O3EzyqCq M4XpOJBz\X[nboTzJJRp\SCjc4PlcYJtgSCxZjDjfZRwe2:uaXOgZ49ifCCycn;0[YlveyCxboTvJGdwdGerIH3lcYJz[W6ncx?= NXPpbYdMOjV5N{K2NVY>
FRT  MkTpSpVv[3Srb36gRZN{[Xl? MlrsOUDPxGdxbXy= NV\NdlhlOsLiaB?= NHLFOHZjdG:la4OgeJJi\m[rY3vpcochfGi{b4XnbEB1cGViR3;s[4kh[2:vcHzlfEBjgSCrbnjpZol1cW6pIFXSMZRwNUexbHfpJJRz[W6|cH;yeC=> M2PuT|I2PzZ5MUG1
FRT  NUL4N2tsTnWwY4Tpc44hSXO|YYm= M3SyRVUh|rypL33s M2iwZlLDqGh? MkfudJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm MkXlNlU4PjdzMUW=
HepG2  MV7GeY5kfGmxbjDBd5NigQ>? Mkn3NgKBkcL3TdMg NG[xWWMzPCCq MYrEUXNQ NYCxemIz\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDQXHIhdVKQQR?= NWP2coFqOjV4MU[1PVc>
SMCs MU\GeY5kfGmxbjDBd5NigQ>? M{fBdVHPxGdxbVy= NGjJb3Q{KGh? M2LEZ4Fk[3WvdXzheIV{KEOQUGmyJJBzd3SnaX6gbY4hfGinIFXSJINwdXCjcoTt[Y51KGGwZDDuc{Btd26pZYKgZ48udG:lYXzpfoVlKHerdHigeIhmKEexbHfpJI1iemunctMg Ml;LNlU2QDl2MkW=
OB-6 NYLM[Hc2SXCxcITvd4l{KEG|c3H5 NH;nXmYzNjgEoN88US=> Mk\zOFghcA>? MnK2bY5lfWOnczDhdI9xfG:|aYO= MkfHNlU2OzJ2OEC=
iPSC-CMs  M{\X[2Z2dmO2aX;uJGF{e2G7 MUS1NFAhdmdxbXy= MYS0PEBp NUGzNXBGcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhfGinIHjp[4hmeiCvb3LpcIl1gSCOQV3Qd{BifCC2aHWgZ49{fCCxZjD0bIUhdG:5ZYKgcY9jcWyrdImgd5Bm[2mncx?= NIXCUGkzPTR6OE[2Oi=>
SP-Nluc NXjifZdwTnWwY4Tpc44hSXO|YYm= M1fQdlUhdWdxbVy= NEjnOYo3KGh? NIHB[phFVVORwrC= MX\jZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl MnLPNlU{QTJ7OUi=
PEXEL-Nluc NEPPPVdHfW6ldHnvckBCe3OjeR?= NWTHbYsxPSCvZz;tUC=> M2PGc|YhcA>? MX7EUXNQyqB? NYroe4l3[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NX;meYxFOjV|OUK5PVg>
H1299 MW\GeY5kfGmxbjDBd5NigQ>? Mlf5NVAh|rypL33s M130flI1KGh? NEjqUYVqdmS3Y3XzJIF2fG:yaHHnfeKh M4OySVI2Ozh6OUew
MDA-MB-231 MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEPDTI4x6oDVNUCg{txoN22O NWHzNGJTPDhiaB?= MnPZSWM2OMLiPTCwMlAyPiEEtXevcWw> MlPsNlU{PTZ3Nke=
MDA-MB-231 NELw[FZCeG:ydH;zbZMhSXO|YYm= NUfYU29nOC5zIN88[{9uVA>? NYC5RpNIPCCq MWrpcoR2[2W|IHHwc5B1d3Orcx?= M3vOPFI2OzV4NU[3
MDA-MB-231 NFzNeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPNE4xOS9yLkC1JO69\y:vTB?= MVmyOEBp Mn;IbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= M1HiXFI2OzV4NU[3
MDA-MB-231 M2PPNmFxd3C2b4Ppd{BCe3OjeR?= M4\YWlAvODYkgKOxJO69\y:vTB?= M2Hk[FI1KGh? M1LXd4lv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= NUToOHBPOjV|NU[1Olc>
MDA-MB-231 M2P4XmZ2dmO2aX;uJGF{e2G7 M3Kxb|DjiJN3MDFOwIcwdUx? NYDqZWw4OjRiaB?= M1fIN4lvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz M4n0e|I2OzV4NU[3
A172 NH7VSoxHfW6ldHnvckBCe3OjeR?= MnntNVDDqM7:Zz;tcC=> MWe0xsBp MV\EUXNQyqB? Mn\KdoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? NEjiWHczPTJ|OUWwOy=>
KMS-6 MWHGeY5kfGmxbjDBd5NigQ>? NXnLfWxMOcLizszNxsA> NUDBXVRPOjRiaB?= NITxcIpmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y= NUD0fIdNOjV{MkmxNlY>
MEC M{DOVWZ2dmO2aX;uJGF{e2G7 MWKxJO69VQ>? M{jOWlEvPSCq NHjTXplk[XW|ZYOgZUBlemGvYYTpZ{Bl\WO{ZXHz[UBqdiC2aHWgd5Vz\mGlZTDWSWdHWjJ? M{\ZdlI2OjJ6OEG1
HEK293/hERG MV7GeY5kfGmxbjDBd5NigQ>? NGjGWnkyOMLizszN NU[wS4NQOcLiaB?= MWTy[ZN2dHS|IHnuJIEhfGmvZT3k[ZBmdmSnboSgdoVlfWO2aX;uJI1ifHW{ZTDoSXJIKHC{b4TlbY7DqA>? MWiyOVIyQDR4OR?=
RBE4 NXLIV3FDSXCxcITvd4l{KEG|c3H5 NFLPNJMzyqEQvF2= NYrHTpVDO+LCk{K0xsBp MYfpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7 M3rYSFI2OTJ6MEK1
RBE4 MYDGeY5kfGmxbjDBd5NigQ>? NYnve|FWOsLizszN NIPjRoU{6oDVMkVCpIg> MXLpcoNz\WG|ZYOgeIhmKFiEUEGgdJJwfGWrbjDs[ZZmdHNiYX\0[ZIhOyCjbnSgOuKhcCCxZjD0doVifG2nboS= MVWyOVEzQDB{NR?=
RBE4 NYPpVZUyTnWwY4Tpc44hSXO|YYm= NVrMWFl[OsLizszN MojkN-KBmzJ2wrDo NH\zfphqdmO{ZXHz[ZMh[WO2aY\lJINie3Cjc3WtNVIhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXGyOVEzQDB{NR?=
RBE4 NIS5W5pHfW6ldHnvckBCe3OjeR?= M1PmU|LDqM7:TR?= MX6z5qCUOjUEoHi= NGnBV4JqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSU3MhfGmvZT3k[ZBmdmSnboTsfS=> MX6yOVEzQDB{NR?=
RBE4 M2PzS2Z2dmO2aX;uJGF{e2G7 NFi5T2YzyqEQvF2= MWSz5qCUOjUEoHi= M3rteYlv\HWlZYOgZUBl\WyjeXXkJIRmeGyndHnvckBw\iC2aHWgSXIhS2F{K9MgZ49vfGWwdDDheEA3yqCqIH;mJIlv[3WkYYTpc44he2mpbnnmbYNidnSueR?= MmnjNlUyOjhyMkW=
RBE4 MnW0SpVv[3Srb36gRZN{[Xl? MVKyxsDPxE1? NG\RR4w{6oDVMkVCpIg> MmDTbY5lfWOnczDhckBwfmW{bH;h[EBw\iCFYUKrxsBqdiC2aHWgcYl1d2Oqb37kdoliKGmwIITo[UBncXK|dDC2xsBpKG:oIHnuZ5Vj[XSrb36gLJDjiIl:4pEJNE4xODFrIHL1eEBE[TJtwrDs[ZZmdHNiaX6geIhqeyCxcnfhcoVtdGViZHXjdoVie2WmIHHmeIVzKDF{wrDoJI9nKGmwY4XiZZRqd25? NFX4TmQzPTF{OECyOS=>
Huh-7  MXnGeY5kfGmxbjDBd5NigQ>? NHvWTHgy|rypL33M NV7xXIhPO+LCk{K0xsBp M3PEd4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MkDHNlUxOjZzN{S=
HepG2  M2C0XWZ2dmO2aX;uJGF{e2G7 NH7mO24y|rypL33M NYHjOph5O+LCk{K0xsBp MVvpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MXyyOVAzPjF5NB?=
H838-LKB1 M2ewZmZ2dmO2aX;uJGF{e2G7 NIXDdmc{OMLibnevcYw> MnGyNVIwOThiaB?= M2HHcIlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> NH;QW2MzPTBzMUC4Ni=>
H838-KDLKB1  MXnGeY5kfGmxbjDBd5NigQ>? MUWzNOKhdmdxbXy= NIXHbnEyOi9zODDo NX24NYtTcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? MV[yOVAyOTB6Mh?=
H838-KDLKB1  NIXXXWZHfW6ldHnvckBCe3OjeR?= NHfzXYM{OMLibnevcYw> M{jHRVEzNzF6IHi= MkG4bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm= MWCyOVAyOTB6Mh?=
3T3-L1 MVLGeY5kfGmxbjDBd5NigQ>? M3jkNlUh|rypL33s MWCzNEBucW5? MnfScYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? M{W2VVI1QDR|OEK3
3T3-L1 MXTGeY5kfGmxbjDBd5NigQ>? M3\nblUh|rypL33s MYmzNEBucW5? NH;Rd3Fz\WOjcHn0eYxifGW|IHnud5VtcW5iYXP0bY9vKHerdHigdoV{eGWldDD0c{Bz\We3bHH0bY5oKEGtdDDhZ5Rqfmm2eTDhcoQhSVNzNkCgdIhwe3Cqb4L5cIF1cW:w NWDHeVY4OjR6NEO4Nlc>
3T3-L1 NVeyeY1OTnWwY4Tpc44hSXO|YYm= MYG1JO69\y:vbB?= M1HDPVMxKG2rbh?= NH\uR3Nk[XW|ZYOgdoV3\XK|aXLs[UBz\WSrc4TybYJ2fGmxbjDv[kBIVFWWNB?= M3;Lc|I1QDR|OEK3
3T3-L1 MXHGeY5kfGmxbjDBd5NigQ>? NEnrN2E2KM7:Zz;tcC=> M{HpfVHDqGh? MVPjZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> MV6yOFg1Ozh{Nx?=
3T3-L1 M3\YcmZ2dmO2aX;uJGF{e2G7 MVS1JO69\y:vbB?= M{PJ[lHDqGh? NHnB[4Rk[XW|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5Rweg>? MmnQNlQ5PDN6Mke=
HeLa  M2jzZ2Z2dmO2aX;uJGF{e2G7 MU[1JO69\y:vbB?= MnHWN{Bp NWTtT3E3[2G3c3XzJI52[2ynYYKg[ZhkdHW|aX;uJI9nKHSqZTDGc5hQOSC2cnHud4NzcXC2aX;uJIZi[3SxcjDhcoQh\GWlcnXhd4V{KHS{YX7zZ5JqeHSrb36gc4YhTm:6T{GtdoVofWyjdHXkJIdmdmW| MYqyOFg1Ozh{Nx?=
HEK293 MXjGeY5kfGmxbjDBd5NigQ>? MWq1xsDPxGdxbXy= NVjOWlRvOTMEoHi= MmHUZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> MlzGNlQ3QDd2M{G=
COS-1 MlnxSpVv[3Srb36gRZN{[Xl? NFK4fXE2KML3Zz;tcC=> MmTYNlQhcMLi NFnTWoJz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>? NVrH[oFsOjR4N{G3OVE>
PRP NHvMT49HfW6ldHnvckBCe3OjeR?= M4r1WVExKM7:TR?= M{P2e4Fjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi NIrG[WwzPDZ4OEe1NC=>
RAW264.7 NHLXWmxCeG:ydH;zbZMhSXO|YYm= MlfnOEDPxE1? M3\6SFQ5KGh? NXPhcYNK[XS2ZX71ZZRmeyC2aHWgbY5pcWKrdHnvckBw\iCxeD3MSGwucW6mdXPl[EBieG:ydH;zbZMh[W6mIITo[UBn[WOrbHn0ZZRqd25ib3[gZ4hwdGW|dHXyc4wh\W[obIX4JIJ6KEGlLXjFMVE5SS2QSEK= NYHkd21lOjR4M{mwN|I>
MDMs MYDBdI9xfG:|aYOgRZN{[Xl? MX[xNQKBkc7:Zz;tcC=> MWOxNk8yPSCq NIHjV2dqdmS3Y3XzJIFxd3C2b4Ppdy=> M1PPXlI1PTV4Nkm1
PMHs  NGLyeWVHfW6ldHnvckBCe3OjeR?= NGnIV5AyOOLCk{Kw5qCK|rypL33s NIj0ZZMzPOLCiXi= MoXTSG1UVw>? NWHkfYdIcW6mdXPl[EBGWiC|dILld5M> NFq5dpUzPDRyN{K0Ni=>
PMHs  NIrQ[pVCeG:ydH;zbZMhSXO|YYm= MmfxNVDjiJN{MPMAje69\y:vbB?= M4i0OFI16oDLaB?= MlHGSG1UVw>? MVHpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> NWDNOYlzOjR2MEeyOFI>
HEK293/tau NVvqXYNWTnWwY4Tpc44hSXO|YYm= NUThfFNQPSEQvF2= NH:5O28yNzJxNDDo M1ryXIlv\HWlZYOgS49t\2liZoLh[41mdnSjdHnvcuKh NHH1dnYzPDN4OEC4PS=>
HEK293/tau NUPWPJVtTnWwY4Tpc44hSXO|YYm= NWDTSWk{PSEQvF2= MXizJIg> Mm\qbY5lfWOnczD0ZZUhcHmyZYLwbI9{eGixconsZZRqd25? MXeyOFM3QDB6OR?=
ADF M3XQXmZ2dmO2aX;uJGF{e2G7 MUOxNEDPxE1? NH7aXoEyPiCq NF7USJZqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? MUeyOFIzQDJ|Mh?=
U373  MYPGeY5kfGmxbjDBd5NigQ>? NI\HTpMyOCEQvF2= Mny4NVYhcA>? NHfnbG1qdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? Mlf0NlQzOjh{M{K=
RKO-HIPK2i MXTGeY5kfGmxbjDBd5NigQ>? MkX6NVAh|ryP MkO3NVYhcA>? MoHMbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MkO3NlQzOjh{M{K=
ADF  NYDyWVhMTnWwY4Tpc44hSXO|YYm= NUPiR5JqOTBizszNxsA> MV22JIg> NIm0eFNqdXCjaYLzJJRp\SCGQzDhZ5RqfmG2aX;u MkPmNlQzOjh{M{K=
Huh7 M2\XUmZ2dmO2aX;uJGF{e2G7 M{nBUFUh|rypL33s M1voc|QhcA>? NEfxfHdi[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D NXvvZ5ZFOjRzMECxOFA>
Huh7 M4XjfmZ2dmO2aX;uJGF{e2G7 MVm1JO69\y:vbB?= NVO5dHI{OSCq NVfMe2Nj[2G3c3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6gRZBwSi2lcnXzZ4VvfHN? NFixSHEzPDFyMEG0NC=>
Huh7 Mnq4SpVv[3Srb36gRZN{[Xl? NXXzc49zPeLCk{GwxsBv\y:vbB?= NIXGcoEyOiCq NIfRVplqdmO{ZXHz[ZMhSXCxQj3jdoV{[2WwdIOge4l1cG:3dDDpcohq[mm2aX7nJJNm[3KndHnvci=> MXiyOFExODF2MB?=
BAECs NVPwdWhtTnWwY4Tpc44hSXO|YYm= Mo\YOUDPxGdxbXy= MnPwNE01KGh? MVPpcoR2[2W|IITo[UBz[XCrZDDk[ZBpd3OyaH;yfYxifGmxbjDv[kBmVk:VIHH0JHNmejFzN{m= MXqyOFA5PTJ{NR?=
Macrophages M13wRmZ2dmO2aX;uJGF{e2G7 NUTGXYdKPzFiwsXN MWS2JIg> NFWyO3lqdmirYnn0d{BtfW6jc3nuJIlvfGW{bnHsbZpifGmxbtMg NUPaZWxSOjRyM{m3OFA>
Colo 205 M2TQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMVUh|rypL33M MkDUOFghcA>? MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O NYL1dWU6OjN7N{O5PVY>
Colo 205 NEHaVpBHfW6ldHnvckBCe3OjeR?= NXHmUJh7OC5yMUKtNE4xOjVizsznM41N MXOxOEBl Ml;xdoVlfWOnczD0bIUh[2yxbn;n[Y5q[2m2eTDv[kBEd2yxIEKwOUBEW0O| NIqxVpQzOzl5M{m5Oi=>
Colo 205 M3K3emFxd3C2b4Ppd{BCe3OjeR?= NF\JZowxNjFizsznM41N M1[wV|AuOjRiaB?= MYjpcoR2[2W|IHHwc5B1d3OrczDv[kBEd2yxIEKwOUBk\WyuczDpckB{fXOyZX7zbY9vKGO3bIT1doV{ MXeyN|k4Ozl7Nh?=
Colo 205 Mmi4SpVv[3Srb36gRZN{[Xl? M17GUVAvODF3IN88[{9uVA>? M2XrelI1KGh? MljIbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDFVkB{fHKnc4OtdoVt[XSnZDDn[Y5mew>? MYOyN|k4Ozl7Nh?=
Colo 205 NGnoPYJHfW6ldHnvckBCe3OjeR?= M3jR[VAvODF3IN88[{9uVA>? M2r6XlI1KGh? M1:5VYlvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ MYKyN|k4Ozl7Nh?=
IBRS2 MkHySpVv[3Srb36gRZN{[Xl? M2nIN|Uh|rypL33s MVOwMlUhcA>? NGXPXXVFVVOR MV7kbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> NXXMepF6OjN7NkO1N|Q>
IBRS2 NH3mSXVHfW6ldHnvckBCe3OjeR?= M2PIUlUh|rypL33s MXSwMlUhcA>? MVvEUXNQ NEPRUYhmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= M4\FeFI{QTZ|NUO0
HeLa NHzLb2lHfW6ldHnvckBCe3OjeR?= M{jNd|Ih|ryP MlHmNkBpyqB? MlPIZZR1\W63YYTld{B1cGViVF7GMYlv\HWlZXSgd4VkemW2aX;uJI9nKEmOLUG1 M4DsSVI{QTVyOEmy
HFS  MmfPSpVv[3Srb36gRZN{[Xl? MVywMVEh|rypL33s NHTxWGMzPCCq MmTlS2xVWCCneIDy[ZN{cW:wIILlZYNp\XNiYTDwcIF1\WG3IHH0JINwdmOnboTyZZRqd26|IHHzJIxwfyCjczCwMlAyKML3Zz;tcC=> MorlNlM5QTR4M{O=
HFS  NXnNfJFDTnWwY4Tpc44hSXO|YYm= MXGwMlAyKML3Zz;tcC=> MmDsNlQhcA>? MWTpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[4x6[2:|cHjpcodwdGmyaXSgd5lvfGijc3Wg[4Vv\XNiYYSgOkBp M322dlI{QDl2NkOz
OVCAR-3 M{\vU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr4N4JXOeLCk{G1xsDPxE4EoB?= NGLTZm4zPMLiaB?= MmjDbY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi NYXLdnRYOjN6Mk[5OlQ>
OVCAR-3 Mn7CSpVv[3Srb36gRZN{[Xl? MV:x5qCUOTYEoN88UeKh M17QeVI1yqCq NUHtPJhkcW6mdXPld{BvfWOuZXHyJIRidWGpZR?= MYCyN|gzPjl4NB?=
OVCAR-3 MXjBdI9xfG:|aYOgRZN{[Xl? NH\WRnkyNTFywrFOwG0> NV\zPJNpPCCq Mki0bY5lfWOnczD0bIUh[WO2aY\heIlwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\Wmwcx?= NYDhWXNiOjN6Mk[5OlQ>
OVCAR-3 NVLZNW1jSXCxcITvd4l{KEG|c3H5 NFvYeG8yOMLizszN NF36UVQzPMLiaB?= NIjLSYNqdmS3Y3XzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\XN? NXy4Z4NEOjN6Mk[5OlQ>
OVCAR-3 MVzGeY5kfGmxbjDBd5NigQ>? MoPUNgKBmzFywrFOwG0> Mmj3NlTDqGh? MnjmbY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs NV\MSVhtOjN6Mk[5OlQ>
OVCAR-3 MWDGeY5kfGmxbjDBd5NigQ>? MXux5qCUOTEEoN88US=> MWiyOOKhcA>? NHTZTlBqdmS3Y3XzJIZwem2jdHnvckBw\iC{ZXHjeIl3\SCxeInn[Y4he3CnY3nldy=> NVu4WW5IOjN6Mk[5OlQ>
OVCAR-3 MkX1SpVv[3Srb36gRZN{[Xl? M3L5c|HjiJNzMNMg{txO NVvvPVVbOjUEoHi= NUDrWpBXcW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v M{\CUFI{QDJ4OU[0
MKN45 NXzrRVFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRDBwMECxJO69\y:vbB?= M2nPV|I{Pzl|M{Sy
LOVO M1nxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\HfoZmUUN3ME2wMlEzKM7:Zz;tcC=> MUSyN|c6OzN2Mh?=
A549 NYnSeY5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\lTWM2OD1yLkC0JO69\y:vbB?= NWXhWJN3OjN5OUOzOFI>
MDA-MB-435 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLOTWM2ODxyLkCwNUDPxGdxbXy= NVnCTWkxOjN5OUOzOFI>
HepG2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1TWM2ODxyLkCwNUDPxGdxbXy= MkLRNlM4QTN|NEK=
HL-60 NVXvXJE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRDBwMECxJO69\y:vbB?= M2DBc|I{Pzl|M{Sy

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

- Collapse
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1CCCC=CC2CC(CC2C(C=CC(=O)O1)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID